



NS Result of AGM

RESULT OF AGM

[HELLENIC DYNAMICS PLC](#)

Released 15:17:52 29 September 2023

RNS Number : 2268O
Hellenic Dynamics PLC
29 September 2023

Hellenic Dynamics plc
("Hellenic Dynamics" or the "Company")

Result of Annual General Meeting ("AGM")

Hellenic Dynamics Plc (LSE: HELD), a medical cannabis cultivator with a dedicated focus on producing tetrahydrocannabinol ("THC") dominant strains of medical cannabis flowers for the burgeoning European medical cannabis markets, is pleased to announce that all resolutions put to the AGM were passed by shareholders on a show of hands. The proxy results received ahead of the AGM were:

Resolution	For		Against		Withheld	Total votes cast
	No. of votes	%	No. of votes	%		
ORDINARY RESOLUTIONS						
1. To receive the Company's annual report and accounts for the period ended 31 March 2023	1,955,917,606	100.00	0	0.00	440,466	1,955,917,606
2. To approve the Directors' Remuneration Policy	1,946,616,811	99.95	1,068,295	0.05	8,672,966	1,947,685,106
3. To approve the Remuneration Report	1,946,629,311	99.95	1,055,795	0.05	8,672,966	1,947,685,106
4. To re-appoint Sir Anthony Joliffe	1,946,856,246	99.57	8,456,034	0.43	1,045,792	1,955,312,280
5. To re-appoint Mr Davinder Rai	1,954,623,746	99.96	688,534	0.04	1,045,792	1,955,312,280
6. To re-appoint Mr Filippou Papadopoulos	1,954,629,311	99.97	682,969	0.03	1,045,792	1,955,312,280

7.	To re-appoint Mr Joseph Colliver	1,954,623,746	99.98	456,034	0.02	1,278,292	1,955,079,780
8.	To re-appoint PFK Littlejohn LLP	1,955,467,137	99.98	450,469	0.02	440,466	1,955,917,606
9.	To authorise the Directors to determine the auditor's remuneration	1,955,917,606	100.00	0	0.00	440,466	1,955,917,606
10.	To authorise the Directors to allot shares	1,935,355,786	99.95%	918,068	0.05	20,084,218	1,936,273,854

SPECIAL RESOLUTIONS

11.	To authorise the Directors to disapply pre-emption rights	1,934,702,476	99.92	1,571,378	0.08	20,084,218	1,936,273,854
12.	To authorise calling of a general meeting other than annual general meetings on 14 clear days' notice	1,954,196,001	99.94	1,103,779	0.06	1,058,292	1,955,299,780

Notes:

A vote withheld is not a vote in law and is not counted in the calculation of the percentage of the votes validly cast for or against a resolution.

Enquires:

Hellenic Dynamics plc
Davinder Rai

+44 (0)20 3818 7850
davinder@hellenicdynamics.com

Cairn Financial Advisers LLP
Emily Staples / Jo Turner

+44 (0)20 7213 0880

Peterhouse Capital
Lucy Williams / Charles Goodfellow

+44 (0)20 7469 0930

About Hellenic Dynamics plc

Founded in 2019, Hellenic Dynamics is specifically focused on the cultivation and supply of THC ("tetrahydrocannabinol") - dominant strains of medical cannabis flowers, destined for the growing medical cannabis markets across Europe. Hellenic Dynamics' core strategy is to develop and operate its 40,000 square metre active cultivation licence from its 195,506 square metre facility located near Thessaloniki in Northern Greece. In full production, Hellenic Dynamics is capable of producing over 54,000 kg of dried flowers per annum.

Hellenic Dynamics will take advantage of its relatively low cost base resulting from a comparatively low cost of power, having its own running water supply and the labour rates for skilled and semi-skilled labour in Northern Greece.

25 European countries now allow medical cannabis via prescription and the European cannabis market is expected to reach €43.3 billion per annum by 2027. Sales of Hellenic Dynamics' dried THC-dominant cannabis flowers and extracts are initially intended for export into Europe's largest market - Germany, in addition to other European markets including domestically in Greece.

As the first medical cannabis cultivator to obtain a listing on the main market for listed securities of the London Stock Exchange, Hellenic Dynamics is significantly different to the number of CBD (Cannabidiol) related companies that have appeared over the recent years. Hellenic Dynamics cultivates THC-dominant medical cannabis flowers. THC-dominant medical cannabis products are only available via a medical prescription. Medicinal cannabis has been approved for use both in the United Kingdom and Germany, plus 23

other European countries, for conditions including but not limited to chronic pain, intractable chemotherapy-related nausea, anxiety, insomnia, Tourette's syndrome, substance use disorder, multiple sclerosis, IBS, spinal cord treatment, lack of appetite due to HIV/AIDS, cachexia, anorexia and glaucoma.

For further information please visit our website www.hellenicdynamics.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGLLMITMTBTBAJ

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

© 2023 London Stock Exchange plc. All rights reserved.